Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

42.79
-1.0550-2.41%
Volume:215.26K
Turnover:9.08M
Market Cap:3.67B
PE:-9.85
High:42.86
Open:42.57
Low:41.53
Close:43.84
Loading ...

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Feb

CRISPR Therapeutics Q4 2024 GAAP EPS $(0.44) Beats $(1.13) Estimate, Sales $35.691M Beat $7.657M Estimate

Benzinga
·
12 Feb

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

BofA Securities Adjusts CRISPR Therapeutics Price Target to $86 From $85, Maintains Buy Rating

MT Newswires Live
·
11 Feb

Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities

TIPRANKS
·
11 Feb

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Zacks
·
11 Feb

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand

Reuters
·
11 Feb

Truist Financial Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
10 Feb

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Motley Fool
·
10 Feb

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Zacks
·
07 Feb

CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey
·
07 Feb

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Zacks
·
06 Feb

Cathie Wood-Led Ark Invest Continues to Sell Palantir Shares As Rally Cools Down

Benzinga
·
06 Feb

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

Zacks
·
05 Feb

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Zacks
·
03 Feb